Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxulumis suprachoroidal Triesence in diabetic macular edema
2021-006765-38Phase 2Terminated
- Sponsor
- Oxular Limited
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of triamcinolone acetonide in diabetic macular edema (DME), sponsored by Oxular Limited. Primary endpoints: Safety and tolerability (ocular and systemic adverse events) and Adverse device effects. Started Jan 2022; status: terminated.
02
Drugs
triamcinolone acetonide
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2021-006765-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006765-38.